SCM
ASND icon

Soleus Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Soleus Capital Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-85,000
Closed -$14.7M – 91
2025
Q2 		$14.7M Buy
85,000
+28,700
+51% +$4.67M 0.97% 30
2025
Q1 		$8.77M Sell
56,300
-87,700
-61% -$12.5M 0.63% 41
2024
Q4 		$19.8M Buy
+144,000
New +$18.9M 1.25% 24

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Soleus Capital Management's ASND Position: Q3 2025 in Review

Soleus Capital Management sold out of Ascendis Pharma A/S (ASND) in Q3 2025, closing a stake of 85,000 shares — an estimated $14.7M sold.

Soleus Capital Management first reported a position in ASND in Q4 2024 and held it in 3 quarters. The position peaked at $19.8M in Q4 2024. 279 funds tracked by Wall St. Rank hold ASND as of Q3 2025.

  • Soleus Capital Management reported no remaining Ascendis Pharma A/S position as of Q3 2025 after selling out during the quarter.
  • Soleus Capital Management sold 85,000 Ascendis Pharma A/S shares in Q3 2025, an estimated $14.7M.
  • Soleus Capital Management first reported a position in Ascendis Pharma A/S in Q4 2024 and held it in 3 quarters.
  • Soleus Capital Management's Ascendis Pharma A/S position peaked at $19.8M in Q4 2024.
  • 279 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2025.

Based on Soleus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.